anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides an erlotinib hydrochloride tablet. The erlotinib hydrochloride tablet is prepared from 109-164 parts by weight of erlotinib hydrochloride, 69-104 parts by weight of lactose, 120-180 parts by weight of microcrystalline cellulose, 5-50 parts by weight of sodium carboxymethyl starch, 0.1-1 part by weight of sodium dodecyl sulfate, 10-30 parts by weight of silica, 0.5-10 parts by weight of magnesium stearate and 0-25 parts by weight of a coating agent. The invention also provides a preparation method of the erlotinib hydrochloride tablet. The preparation method solves the problem that the fine raw materials can easily form airborne dust and has high adhesion and a slow dissolution rate. The preparation method utilizes a wet granulation process, improves raw material granularity and utilizes a wetting agent so that material airborne dust is greatly reduced and sticking possibility is reduced. Through wet granulation, the raw materials and accessory materials are uniformly dispersed and bonded with each other and layering possibility is reduced. Through prescription adjustment of silica addition, a raw material dissolution rate is improved. The erlotinib hydrochloride tablet provides a novel choice for clinical application.
Nitazoxanide is an antiprotozoal drug with a well-understood and documented safety profile. It was first approved by the US Food and Drug Administration (FDA) in July 2004 for the treatment of diarrhoea caused by Giardia lamblia or Cryptosporidium parvum in adults (≥ 18 years) and paediatrics (1-17 years). Nitazoxanide has also demonstrated in-vitro anti-SARS-CoV-2 activity. A review of in vitro studies reporting the anti-coronavirus activity of nitazoxanide and its active metabolite, tizoxanide, is available. Nitazoxanide was among the three top inhibitors of coronavirus replication, resulting in a reduction of 6 log10 in virus titer with an IC50 of 1.0 µM. The major circulating metabolite of nitazoxanide is tizoxanide, and it has also been confirmed to have activity against SARS-CoV-216. Both suppress the cytopathic effect of SARS-CoV-2. Nitazoxanide is also active against the influenza A virus and was shown to reduce symptom duration in uncomplicated acute influenza. Since SARS-CoV-2 shares almost 80% of the genome with SARSCoV19 and almost all encoded proteins of SARS-CoV-2 are homologous to SARS-CoV proteins, nitazoxanide and its metabolite tizoxanide with demonstrated activity against SARS-CoV are likely to be effective against SARS-CoV-2. Since the virus replicates quickly, antivirals must remain active across their dosing interval. Therefore, enhanced drug concentration will be needed in the lung throughout the dosing interval.

The HIV protease inhibitor, atazanavir (boosted with ritonavir), has been shown to inhibit the major protease enzyme required for viral polyprotein processing during coronavirus replication. It also blocks pro-inflammatory cytokine production. Similar to nitazoxanide, atazanavir has been shown to achieve effective concentration in the pulmonary tissues at the approved dose of 300 mg in combination with 100 mg of ritonavir, with even more favourable ratios when compared to in vitro activities generated in human cell models.

Therefore, based on these considerations, the combination of nitazoxanide (taken orally at 1000 mg twice daily) and atazanavir/ritonavir (taken orally at 300/100 mg once daily) is being considered for selection for intervention for the treatment of COVID-19. Hence, this study wants to evaluate the clinical usefulness of the combination of these drugs. The approach is to characterise the extent of drug-drug interaction of nitazoxanide and atazanavir/ritonavir when 1000 mg nitazoxanide is taken two times daily in combination with 300/100 mg atazanavir/ritonavir before deploying the combination for the intervention.
The Lay Health Advisor education intervention - The intervention consisted of an intensive, reinforced, one on one, interactive ed. program (an initial meeting, then 2 calls and a series of 4 postcards mailed at regular intervals and a 2nd visit. Woman were enrolled for about 12 to 14 months.
The goal of this study is to evaluate a new method that may influence attention, cravings and substance use called attention training, which will be delivered on a smartphone through an application (app). The study team would like to know what participants think of this new method and to determine if research involving this app is feasible. Eligible participants will use the app for a period of two weeks and attend a total of 4 appointments at our study location. A primary aim of the study is to assess feasibility, usability and acceptability of mobile Attention Bias Retraining (ABR) by quantifying adherence (in lab and natural environment), self-reported ease of use, perceived value and likelihood of future use. Another primary aim of the study is to determine if ABR reduces attentional bias (AB) for opioids in those with Opioid Use Disorders (OUD) compared to a control training condition. A secondary aim of the study is to assess whether ABR reduces opioid craving to a greater extent than a control training condition based on self-report. Another secondary aim is to assess whether ABR is associated with less opioid use during the training period than a control training condition based on self-report and urinalysis. An exploratory aim of the study is to measure levels of self-reported pain pre- and post- ABR. Another exploratory aim is to examine the durability of ABR effect on AB/craving/ opioid use at 1-month follow-up.

Interested individuals will first complete a in-person screening appointment including a medical and psychiatric screening and questionnaires covering topics including substance and alcohol use, cigarette smoking, and sexual behaviors. Eligible participants who enroll in the study will next complete an orientation appointment when study staff will teach participants how to use the study app and answer any questions that arise. Participants will then be randomly assigned (like a flip of a coin) to one of two conditions. Each condition involves use of a smartphone app. One smartphone app includes a task that targets attention directed to substance-related cues while the other app includes a similar task that does not target attention in this way. Neither the participants nor the staff members will know which condition the participant has been randomly assigned to. Participants will be informed of the assigned condition by study staff after the completion of the study. In most prior studies, attention training has been delivered on a desktop computer in a laboratory setting. Initial research has shown that attention training can be used in real-world settings using hand-held devices such as smartphones.
PROBLEM TO BE SOLVED: To obtain a new nucleic acid capable of inducing a secretion of an inflammatory fomites, encoding a primates CTLA-8 protein comprising a specific amino acid sequence, and useful for e.g. producing a therapeutic agent for an abnormal physiological state including an abnormal proliferation, e.g. cancer or degenerative state. SOLUTION: This nucleic acid may induce a secretion of an inflammatory fomites and is 95% the same as an nucleic acid encoding a primates CTLA-8 protein comprising amino acids 26 to 156 of the formula or its fragments. It is useful for e.g. treating a state related to an abnormal physiological state or developmental state including an abnormal proliferation (e.g. cancer) or degenerative state. The new nucleic acid is obtained by screening a man genome library by using a cDNA probe comprising a perfect code sequence of mouse CTLA-8 with 453 base couples.
The invention provides a traditional Chinese medicine capsule for treating hypertension. The traditional Chinese medicine capsule is prepared by processing 15-30 parts of cape jasmine fruit, 15-30 parts of fructus forsythiae, 20-30 parts of chrysanthemum, 25-40 parts of dried rehmannia root, 20-40 parts of earthworm, 10-20 parts of safflower, 20-30 parts of rhubarb, 20-30 parts of Chinese angelica, 15-30 parts of dandelion, 30-45 parts of common selfheal fruit-spike and 10-25 parts of liquoric root. The dandelion, the cape jasmine fruit, the fructus forsythiae and the chrysanthemum are mainly used for clearing upper burner heat. The rhubarb and the common selfheal fruit-spike are mainly used for clearing middle burner heat. The safflower is mainly used for promoting blood circulation and removing blood stasis. The earthworm is mainly used for softening blood vessels. The liquoric root is mainly used for harmonizing. The compatibility of various ingredients can realize the effects of clearing blood poison, harmonizing qi and blood and softening the blood vessels on the premise of being mainly based on clearing of the traditional Chinese medicine theory, the aspects of strengthening vital qi, eliminating pathogenic factor, balancing yin and yang, clearing liver, extinguishing wind, promoting blood circulation, removing blood stasis, suppressing hyperactive yang and reducing pressure of the traditional Chinese medicine are taken as the theoretical foundation, and the clinical verification in more than 300 typical cases proves that the effective rate is 100%.
Desired skin colour is a major unmet consumer need in Asia. Consumers particularly desire even skin colour, absence of age spots (solar lentigines) and lighter overall skin tone. One solution is to use biological actives that reduce the activity of melanocytes in skin. These cells, present in the basal layer of the epidermis, make the darkly coloured pigment melanin and export it in small export vesicles called melanosomes to the neighbouring keratinocytes. It is well described in the literature that compounds which reduce melanin synthesis when topically applied to the skin will reduce skin darkness over time. This invention relates to a composition comprising climbazole for use in skin lightening. This invention is based on the fact that climbazole has been found to inhibit pigment production in B16 monolayer and MelanoDerm™ cultures. Thus climbazole, when applied topically over an appropriate length of time in-vivo, would be expected to cause skin lightening, or to reduce blemishes and/or hyperpigmented spots and/or solar lentigines leading to an improvement in skin tone and evenness.
Uncovering the molecular changes at the site where Aβ is deposited plays a critical role in advancing the diagnosis and treatment of Alzheimer's disease. However, there is currently a lack of a suitable label-free imaging method with a high spatial resolution for brain tissue analysis. In this study, we propose a modified desorption electrospray ionization (DESI) mass spectrometry imaging (MSI) method, called segmented temperature-controlled DESI (STC-DESI), to achieve high-resolution and high-sensitivity spatial metabolomics observation by precisely controlling desorption and ionization temperatures. By concentrating the spray plume and accelerating solvent evaporation at different temperatures, we achieved an impressive spatial resolution of 20 μm that enables direct observation of the heterogeneity around a single cell or an individual Aβ plaque and an exciting sensitivity that allows a variety of low-abundance metabolites and less ionizable neutral lipids to be detected. We applied this STC-DESI method to analyze the brains of transgenic AD mice and identified molecular changes associated with individual Aβ aggregates. More importantly, our study provides the first evidence that carnosine is significantly depleted and 5-caffeoylquinic acid (5-CQA) levels rise sharply around Aβ deposits. These observations highlight the potential of carnosine as a sensitive molecular probe for clinical magnetic resonance imaging diagnosis and the potential of 5-CQA as an efficient therapeutic strategy for Aβ clearance in the early AD stage. Overall, our findings demonstrate the effectiveness of our STC-DESI method and shed light on the potential roles of these molecules in AD pathology, specifically in cellular endocytosis, gray matter network disruption, and paravascular Aβ clearance.
Flavored water. Participants will be asked to consume the study product once a day for 8 to 14 weeks if they have normal weight or excessive weight, respectively.
Episodic future thinking (EFT) strengthens self-regulation abilities by increasing the perceived value of long-term reinforcements and reducing impulsive choice in delay discounting tasks. As such, EFT interventions have the potential to improve dietary and eating-related decision-making in individuals with obesity or binge eating symptoms, conditions associated with elevated delay discounting. Here, we meta-analyzed evidence from 12 studies that assessed whether EFT interventions improve delay discounting and real-world food choice compared to control interventions. Included studies involved 951 adults with overweight or obesity (body mass index [BMI] ≥25). There were no studies involving participants with binge eating disorder. EFT intervention pooled effects were significant, improving delay discounting with a medium effect, g = 0.55, p < 0.0001, and subsequent food choice outcomes with a small effect, g = 0.31, p < 0.01. Notably, our review is the first to analyze mechanisms of effect in this population, demonstrating that improvements were greater when temporal horizons of EFT episodes were aligned with delay discounting tasks and more distant horizons predicted far-transfer to subsequent dietary and eating-related choices. Our findings thus show that EFT is an effective intervention for individuals with higher weight at risk of adverse health consequences.
The present invention relates to a formula and a technology of a product capable of inhibiting hyperplasia of the prostate. In the present invention, drone chrysalis is adopted as the main material, and queen bee larvae and/or pollen is adopted as the auxiliary material. The production technology comprises the steps that drone chrysalis, queen bee larvae and/or pollen meeting the requirements are extracted, concentrated and mixed according to specification; then, the mixture is freeze-dried and pulverized, and finally is prepared into products. The present invention overcomes the insufficiencies of the existing traditional Chinese medicines and chemical compounded medicines, and fills a blank in the field by utilizing drone chrysalis, queen bee larvae and/or pollen to inhibit hyperplasia of the prostate. The present invention determines the optimal formula for inhibiting hyperplasia of the prostate, and the product has the advantages of obvious use effect and no toxic or side effect. Besides, the production technology is advanced, and the active ingredients of the drone chrysalis and the queen bee larvae and the effective extraction rate of the pollen are fully reserved through the technologies of extraction, freshness preservation and freeze drying. In addition, the present invention does not have pollution to people and environment.
Patients with ALK fusion receive ceritinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
PURPOSE:To reduce methemoglobin concentration in blood of plant-eating animal and to prevent nitrate poisoning, by feeding denitrifying bacteria to plant-eating animals. CONSTITUTION:Denitrifying bacteria (e.g. Rhodopseudomonas sphaeroides forma sp. denitrifricans) belonging to the genus Rhodopseudomonas is fed to plant- eating animals such as cow, horse, pig, goat, etc. The bacteria are orally administered in the form of a culture solution and a dose of the culture solution is 500-1,000ml. A cell amount in 1,000ml culture solution is 3g by set weight and 1/5-1/6 the weight by dry weight. Nitrogen in the form of nitrate necessarily taken by eating grass is positively made harmless by administration of the bacteria, nitrate poisoning is prevented and plant-eating animals in the field of dairy farming can be maintained in a healthy state.
A new and useful EMR template functionality for workflow management and workflow information capture is provided. The EMR template functionality is configured with the following characteristics; (a) user configurable workflow specific structured language options, (b) the ability to be kept open to changes and new inputs across the process to which the template refers, (c) the ability to enable selection of a user or user group as a responsible actor in the workflow, (d) the capability to distinguish the template from all other templates (without described workflow functionality) associated with the EMR, and (e) workflow specific searchable data fields. Thus, the template can be configured not only to provide patient medical information, but also to capture workflow information (e.g. insurance authorization, procedure scheduling, etc.), which enables the EMR to track a patient process over time, with regard, e.g. to the state of the workflow ordered for the patient, and thereby gives a medical office or other treatment environment an effective management tool to manage the medical office or other treatment environment's function and to provide effective patient care.
The metabolic syndrome is increasingly being recognized as a major threat to good health - especially cardiovascular health - and its frequency appears to be increasing in relation to the current epidemic of obesity. The objective of this study is to determine whether a program of enhanced lifestyle intervention can, compared to standard care, reduce the frequency and severity of the metabolic syndrome as assessed by clinical, metabolic, inflammatory and vascular outcome measures. The project will compare the effects of Enhanced Care (EC) in 112 patients (80 completers) to Standard Care (SC) in 112 patients (80 completers) over a 12-month period. Following 3 run-in sessions given to both SC and EC participants, eligible subjects randomized to SC will receive lifestyle modification advice as recommended management of the metabolic syndrome and this will be administered at the baseline and the 6 month assessment visits. EC will consist of a 17-session structured, lifestyle intervention plan, directed at achieving weight reduction and increasing physical activity change through education, behavior modification and stress management, and conducted in groups. It will comprise a 3-month Core Curriculum of 8 sessions, followed by a Maintenance phase with 9 monthly sessions delivered by lifestyle counselors, experienced in breaking through barriers in working with socioeconomically disadvantaged members of minority groups. All participants will have baseline, 6-monthly and 1-year assessments. This project, Project 2, entitled Community Health Approaches to Reducing Risk in the Metabolic Syndrome (CHARMS), seeks to study psychosocial and behavioral (lifestyle) variables that may contribute to the progression or amelioration of atherosclerotic processes underlying the pathogenesis of coronary heart disease (CHD). Outcome variables will include measures of glycemic control/insulin resistance and/or dyslipidemia, oxidative stress, inflammation and overt manifestations of disease.
The invention executes a novel patient workflow process on a tablet PC streamlines office visits allowing doctors to see more patients, maximize practice revenues and speed reimbursements, all of which significantly improves the doctor's quality of work and quality of life. The invention maintains and improves patient provider communication optimizing the encounter workflow. The invention, as a point-of-care product, is delivered on a wireless Tablet PC using secure wireless technology. The invention speeds the collection of information while allowing the physician to maintain eye contact with the patient. The invention allows the doctor to easily search, organize and display any information on patients, prescriptions and symptoms, in real time. Using embedded encryption and compaction technologies, the invention assures patient data is secure and meets HIPAA requirements. The invention improves Doctor/Patient Interaction, Communication and Relationship. The invention utilizes handwriting and voice capture and recognition. Routine activities are speeded by customizable templates and forms, check-lists and action lists adapted to each physician's style. Using the invention will reduce annual patient workflow costs, due to electronic collection and submission of transcriptions, coding, prescription, insurance, and referral information.
The first VerifyNow ARU measurement will be done minimum 2 hours and at latest 24 hours after the first four doses of ASA. If the ARU is ≤ 549, the current daily ASA dose will be continued and the patient will be discharged with this dose. If the ARU is ≥ 550, the dose will be increased by 50 mg and the test is repeated after two doses. We will increase the dose step by step until the ARU decreased below 550 or a maximum ASA dose of 300 mg per day is reached. If there is no sufficient drug effect at the maximum dose assessed by VerifyNow, the patient will be count as non-responder and a change to a P2Y12-inhibitor (e.g. Clopidogrel 75 mg) is indicated. A resistance against Clopidogrel will not be examined. The other tests will be held at the first follow-up visit and six months after implantation.
Systems and methods for physical authentication of medical devices during wireless pairing are disclosed herein. The method can include receiving a request to initiate coupling. Following the request, a visual identifier can be generated with a light source. The visual identifier can include embedded data used to couple the medical devices. The visual identifier can be captured in image data, which image data can be analyzed and the embedded data can be extracted from the image data. Based on the embedded data that is extracted from the image data, secure coupling between medical devices can be established.
People with ankylosing spondylitis (AS) are vulnerable group to experience mood disorders. It is crucial to identify factors that contribute to depression and anxiety in order to improve outcomes. This study seeks to determine the rates of depression and anxiety in Syrian AS patients, as well as identify potential predictors for these conditions. This cross-sectional study was conducted using convenience sampling at the Biological Treatment Unit of the Rheumatology Department of the Damascus Hospital. Data were collected from face-to-face interviews with patients using validated structural questionnaire. A multivariate linear regression model was used to investigate potential predictive factors of depressive and anxiety symptoms. Of the 103 patients, 49.5% showed clinically significant depressive symptoms, and 36.9 % showed clinically significant anxiety symptoms. Multivariate linear regression indicated that depressive and anxiety symptoms were predicted by job layoff, hip pain, positive history of mental distress, poor quality of life, severe fatigue, and high frequency of sleep disturbance with relatively high explanatory powers. depressive and anxiety symptoms were predicted by disease activity scores but with low explanatory power. This study demonstrated high levels of that depressive and anxiety symptoms among Syrian patients with AS undergoing biological treatment. Poor quality of life, severe fatigue, and high-frequency sleep disturbances are major predictive factors for depressive and anxiety symptoms. Screening for depression and anxiety holds significant importance in the comprehensive management of ankylosing spondylitis even in the context of concurrent biological treatment administration.
Participants will be asked to break their sitting time by standing for five minutes every 30 minutes. Participants will be asked to stand in the same position with no further instructions provided. In total, individuals will accumulate 12 bouts (60 minutes) of standing throughout the test period.